Introduction

Metabolic syndrome (MS) is a complex condition predisposes the population to an increased risk of cardiovascular diseases (CVD). It is characterized by at least three risk factors: elevated blood pressure, triglycerides, glycemia, waist circumference, and reduced levels of HDL-C. These clusters of factors increase inflammatory and oxidative processes that promote and aggravate other metabolic conditions that increase morbidity and mortality (1,2).

Subjects with MS usually develop diabetes, dyslipidemia,
hypertension, and abdominal obesity. This condition, which is more common in adults, is also increasing in children and adolescents. This is due to unhealthy lifestyle habits with high consumption of carbohydrates, fats, processed and ultra-processed foods, and lack of physical exercise. Thus, lifestyle modification strategies, drug treatment, and adjuvant therapies are essential to improve risk factors. Medicinal plants and natural compounds have gained ground in the therapeutic approach to MS due to their effectiveness, reduced costs, and few adverse effects. Among many plants with positive impacts to improve MS risk factors is *Curcuma longa* (3-5).

*Curcuma longa*, popularly known as or turmeric, belongs to the family Zingiberaceae, which grows in Indian and tropical countries and has been used in Indian Ayurvedic medicine for more than 6,000 years. Due to its golden color and slightly bitter taste, turmeric is considered a versatile spice and is very used in culinary preparations (6-8).

Turmeric shows diversity in its chemical composition, and the quality and amount of the bioactive compounds can vary according to locations and growing conditions. Many phenolic compounds and terpenoids are present in this plant. The main compounds of the rhizomes are curcuminoids: curcumin (77%) that is responsible for the yellow color bisdemethoxycurcumin (17%), and demethoxycurcumin (3%) (9,10). Curcumin is broadly used as a color-inducing agent and was designated as a food additive, and is Generally Recognized as Safe by the American Food and Drug Administration (11).

Several studies have shown that *Curcuma longa* can benefit the treatment of several pathological conditions since it exhibits anti-inflammatory, antioxidant, antimicrobial, antibacterial, antiviral, antifungal anti-hypoglycemic, antiobesity, anti-hypertension, neuroprotective, antidepressant, and chemo-preventive (12-14). Figure 1 shows the main compounds and some effects of *Curcuma longa*.
Due to the properties mentioned earlier of *Curcuma longa*, this study aims to perform a systematic review of the effects of this plant on MS.

We present the following article in accordance with the PRISMA reporting checklist (available at https://dx.doi.org/10.21037/lcm-21-25).

**Methods**

**Focal question**

The focal question for this systematic review was: Can *Curcuma longa* show benefits on MS?

**Language**

Only studies published in English were selected.

**Databases**

This review was built with studies published in PubMed, EMBASE, and COCHRANE databases. The mesh-terms were *Curcuma longa* or curcuminoids or curcumin and MS. PRISMA (Preferred Reporting Items for a Systematic Review and Meta-Analysis) guidelines were used to perform this review (15) (Figure 2).

### Study selection

This review was built with studies that associated *Curcuma longa* or *Curcuminoids* or curcumin [Code of Federal Regulations (FDA): §73.600] and MS. The inclusion criteria enclosed Randomized clinical trials (RCTs), double-blind RCTs, and placebo-controlled studies. We only used full-text studies that were performed with MS patients and not those with the plant and isolated MS risk factors. We also considered PICO (population, intervention, comparison and outcomes) format.

The exclusion criteria were studies not in English, reviews, studies with animals or *in vitro*, clinical trials that associated different plant formulations, case reports, poster presentations, and editorials. Reviews were examined to build the discussion but were not included in the systematic review.

---

**Figure 2** Flow diagram showing the study selection.
Data extraction

The period for the search included clinical trials performed in the past ten years (February 2011 to June 2021). Two judges performed data extraction. A third judge resolved disagreements between them.

The selected studies are included in Table 1.

Quality assessment

The quality of the included studies followed the Cochrane Handbook for Systematic Reviews of Interventions was used to perform this quality assessment.

Results

Table 1 shows the results of this systematic review. After using the inclusion and exclusion criteria, eleven randomized trials that investigated the effects of Curcuma longa in patients with MS were included. Both sexes were present in all the studies. Most of them were double-blinded studies. Of these studies, five (22-26) have used the same group of patients from Iran, and the other four, also in Iran (17,18,20,21), present this same characteristic. The other studies were performed in Taiwan (16) and Italy (19).

The studies presented in Table 1 show that Curcuma longa can bring benefits in patients with MS. These studies showed that this plant can improve Body Mass Index, weight gain, glycemia, lipids (reduction of triglycerides and increase of HDL-C), adiponectin, C reactive proteins, and cytokines levels [tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), and monocyte chemoattractant protein-1 (MCP-1)]. No severe adverse effects were reported in the included studies. In Table 2 we show the risk of bias for the included studies.

Discussion

MS

MS has a multifactorial etiology and is considered one of the major public health problems in people worldwide. It is observed that rates of 30% can afflict some populations and the consequences are a high burden to health systems. There are different diagnostic criteria for MS, but most enclose risk factors for developing CVD. These risks are altered levels (high levels) of blood glucose and triglycerides, obesity, hypertension, and reduced HDL-C (27-29).

The National Cholesterol Education Program ATP III (NCEP ATP III) criteria comprise the presence of any three of the following conditions: fasting glucose ≥110 mg/dL; triglycerides levels ≥150 mg/dL; HDL-C levels ≤40 mg (men) or ≤50 mg/dL (women); waist circumference (WC) ≥102 cm (men) or ≥88 cm (women); and blood pressure ≥130/85 mmHg. The criteria established for the International Diabetes Federation (IDF, 2006) considers fasting glucose ≥100 mg/dL, triglycerides levels ≥150 mg/dL; HDL-C levels ≤40 mg (men) or ≤50 mg/dL (women); WC >90 cm for men and >80 cm for women; and blood pressure ≥130/85 mmHg. Following IDF (2006), the patient has MS when possessing altered WC with the presence of two other risk factors (IDF, 2006) (2,30-33).

The multisystemic character of MS denotes that many chronic-degenerative diseases that are also associated with oxidative stress, a pro-inflammatory state, and atherosclerosis are superimposed in “dysmetabolic” subjects. The most common associated conditions are CVD, non-alcoholic steatohepatitis, chronic kidney disease, neurodegeneration, and cancer (34-38).

Understanding the components of MS and its metabolic and systemic repercussions is essential to take measures to contain the progression of the number of affected patients. Lifestyle changes are imperative; however, the search for therapeutic strategies that control risk factors is important to reduce the long-term complications of MS. Medicinal plants and their bioactive compounds can collaborate to prevent or treat risk factors at attractive prices and low side effects.

Curcuma longa, curcumin, and MS

Curcuma longa and its derivatives, such as curcumin, have been used for medical purposes to treat several conditions since ancient times. Many of the effects of this plant are related to its antioxidant and anti-inflammatory properties. Several diseases are related to inflammation and oxidative damage. Oxidation leads to chronic inflammation, and chronic inflammation increases oxidative stress. Alone or together, these conditions mediate most known chronic diseases. Hyperglycemia, for example, can lead to the increased entrance of glucose in non-insulin-dependent tissues and cause the production of advanced glycation products (AGEs), which are reactive species related to numerous events that trigger metabolic changes. Obesity is considered a low-grade inflammatory process that leads to a shift in the secretory pattern of macrophages from M2 (related to the release of anti-inflammatory mediators)
Table 1 Descriptive table of the included studies

| Reference | Local | Patients | Intervention and time of intervention | Outcomes | Adverse effects |
|-----------|-------|----------|---------------------------------------|----------|----------------|
| Yang et al. (16) | Taiwan | Randomized, double-blind, placebo-controlled trial with 65 ♂ and 31 ♂ subjects (59.03±12.00 y) with MS who have had stable medical treatment for at least 6 m prior to the study enrollment | Subjects were randomized into 2 groups: curcumin (n=33, 12 ♂, 59.03±10.10 y, 600 mg curcumin extract capsule 3× d) and placebo (n=32, 17 ♂, 59.61±14.09, placebo capsule 3× d/12 w | Subjects that received curcumin presented anti-epileptic effects but the intake was not associated with weight or glucose homeostasis | Two participants in the curcumin group had mild diarrhea and nausea as adverse effects |
| Panahi et al. (17) | Iran | Randomized, double-blind, placebo-controlled, parallel-group design trial with 117 ♂ and 38 ♂ subjects (25-75 y) with MS | Subjects were randomized into 2 groups: curcumin (n=59, 44.80±8.67 y, 23 ♂, 1,000 mg/d+10 mg of piperine to improve the bioavailability of the curcumin) and placebo (n=58, 43.46±9.70 y, 27 ♂, 1,000 mg of placebo+10 mg of piperine)/w | Curcumin significantly reduced serum LDL-C, non-HDL-C, total cholesterol, triglycerides, and Lp(a). Curcumin elevated HDL-C | Diarrhea (n=2), constipation (n=2), headache (n=1), and skin rash (n=2) in the curcumin group. Headache (n=2) and constipation (n=1) in the placebo group |
| Pahani et al. (18) | Iran | Phase III, randomized, double-blind, placebo-controlled study with a parallel-group design. This study had 117 ♂ and 38 ♂ subjects with MS and that were not receiving lipid-lowering therapy | Subjects were randomized into 2 groups: curcumin (n=59, 44.80±8.67 y, 23 ♂, 1,000 mg/day+10 mg of piperine to improve the bioavailability of the curcumin) and placebo (n=58, 43.46±9.70 y, 27 ♂, placebo)/w | Curcumin-pipeline combination significantly improved superoxide dismutase activities and reduced malondialdehyde concentrations. The treated group showed reduced circulating CRP and significantly improved oxidative and inflammatory ambiances | NR |
| Di Pierro et al. (19) | Italy | Randomized, controlled clinical trial with 17 ♂ and 27 ♀ overweight subjects (18-75 y) with BMI between 25.0-29.9 under 10 d with diet or with another intervention of lifestyle and have shown less than 2% of weight loss | Subjects were randomized into group 1: 800 mg/dose of Curcuma longa extract with 95% of curcumin + lifestyle intervention, and G2: phosphatidylserine + lifestyle intervention (400 mg/dose of pure phosphatidylserine)/m | Participants of group 1 presented a reduction in the weight and fat percentage, improved hip circumference reduction, and enhanced BMI reduction (these effects were not significant in G2) | Gastric burning in phosphatidylserine group |
| Pahani et al. (20) | Iran | Randomized, double-blind, placebo-controlled trial with parallel group design with 117 ♂ and ♂ with MS and that were not receiving lipid-lowering therapy | Subjects were randomized into 2 groups: curcumin (n=59, 44.80±8.67 y, 23 ♂, 1,000 mg/d+10 mg of piperine/day to improve the bioavailability of the curcumin) and placebo (n=58, 43.46±9.70 y, 27 ♂, placebo)/w | Curcumin was associated with a significant elevation in serum adiponectin and reduction in leptin levels | Diarrhea (n=2), constipation (n=2), headache (n=1), and skin rash (n=2) were reported in the curcumin group. Headache (n=2) and constipation (n=1) in the placebo group |
| Pahani et al. (21) | Iran | Randomized, double-blind, placebo-controlled trial with 117 ♂ and ♂ subjects with MS and that were not receiving lipid-lowering therapy | Subjects were randomized into 2 groups: curcumin (n=59, 44.80±8.67 y, 23 ♂, 1,000 mg/d+10 mg of piperine) and placebo (n=58, 43.46±9.70 y, 27 ♂, placebo)/w | The curcumin supplementation was associated with a significant decrease in serum cytokines levels (TNF-α, IL-6, TGF-β and MCP-1) of subjects with MS | Diarrhea (n=2), constipation (n=2), headache (n=1), and skin rash (n=2) in the curcumin group. Headache (n=2) and constipation (n=1) in the placebo group |
| Ghazimoradi et al. (22) | Iran | Randomized, double-blind, placebo-controlled study with 120 ♂ and 90 ♀ participants (18-65 y) affected with MS and BMI between 25.5-28.9 under 10 d with diet or with another intervention of lifestyle and have shown less than 2% of weight loss | Subjects were randomized into 3 groups: phospholipidated curcumin (1,000 mg of phospholipidated curcumin), curcumin (1,000 mg/d), and placebo/w | In the final analysis of the study, the results showed that the supplementation with curcumin did not suggest any improvements of pre-oxidant-antioxidant balance in patients affected by MS | Nausea (n=1 group 1), and abdominal pain (n=1 placebo group) |
| Mohammadi et al. (23) | Iran | Randomized, placebo-controlled clinical trial with 120 ♂ and ♀ participants (18-65 y) diagnosed with MS and that did not receive nutritional supplements and drugs in the past 3-6 m before the study | Subjects were randomized into 3 groups: phospholipidated curcumin (n=40, 500 mg/dose of phospholipidated curcumin/4 w), phospholipidated curcumin (n=40, 500 mg/dose/6 w), and placebo (n=40, 500 mg/dose/6 w) and placebo group | Any curcumin formulations used in the study interventions suggested significant effects on serum levels of vitamin E | Group 1: hypersensitivity (n=1, sneezing and cold sore). Group 2: cold sore (n=1) and nausea (n=1) |
| Mohammadi et al. (24) | Iran | Randomized, double-blind, placebo-controlled clinical trial with 120 ♂ and ♀ subjects (18-65 y) diagnosed with MS | Subjects were randomized into 3 groups: curcumin (n=40, 500 mg/2×d for 6 w, 31 ♂, 37.52±8.47), placebo (n=40, 500 mg/2×d/6 w, 25 ♂, 40.05±10.48 y), and placebo (500 mg/2×d, 30 ♂, 38.59±10.28) | Both curcumin and phospholipidated curcumin supplementations did not show effects on serum levels of anti-Hsp 27 in patients with MS | NR |
| Safarian et al. (25) | Iran | Randomized, double-blind, placebo-controlled study with 120 ♂ and 90 ♀ participants (18-65 y) diagnosed with MS | Participants were randomized into 3 groups: phospholipidated curcumin (n=40, 500 mg/dose/6 w) and placebo (n=40, 500 mg/2×d/6 w) and placebo (n=40, 30 y, 38.5±10.2 y, 1,000 mg of placebo/d/6 w) | Serum Zn/Cu levels in phospholipidated curcumin and in curcumin groups were higher than control group, being more significant in the phospholipidated curcumin group. | One subject of the phospholipidated curcumin group did not complete the study because of nausea, as well as 2 participants of the curcumin group because of cold sore and nausea and 1 participant of the placebo group because of abdominal pain |
| Shirmohammadi et al. (26) | Iran | Randomized, double-blind, placebo-controlled with 80 ♂ and ♀ subjects (18-65 y) with MS | Participants were randomized into 2 groups: treatment (curcumin-phospholipid complex group, 40.05±10.48 y, 25 ♂, 1,000 mg of curcumin-phosphatidylcholine complex for 6 w, n=40) and control (placebo, 38.59±10.28, 30/18 w) | The study intervention with curcumin-phospholipid complex did not suggest any significant effects of the curcumin complex on the serum levels of cathespin D of the participants diagnosed with MS | In the phospholipidated curcumin group, 1 subject dropped out the study due to nausea. In the placebo group, 1 subject dropped out due to abdominal pain |

y, year; m, month; d, day; w, week; MS, metabolic syndrome; NR, not reported; CRP, C reactive protein; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; TGF-β, transforming growth factor-β; MCP-1, monocyte chemoattractant protein-1.
Table 2 Descriptive table of the biases of the included RCTs.

| Reference            | Question focus | Appropriate randomization | Allocation blinding | Double-blind | Losses (<20%) | Prognostics or demographic characteristics | Outcomes | Intention to treat analysis | Sample calculation | Adequate follow-up |
|----------------------|----------------|---------------------------|---------------------|--------------|---------------|---------------------------------------------|----------|---------------------------|-------------------|-------------------|
| Yang et al. (16)     | Yes            | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | No                        | NR                | No                |
| Pahani et al. (17)   | Yes            | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | Yes                       | Yes               | NR                |
| Pahani et al. (18)   | Yes            | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | Yes                       | Yes               | NR                |
| Di Pierro et al. (19)| Yes            | Yes                       | No                  | No           | Yes           | Yes                                         | Yes      | Yes                       | Yes               | NR                |
| Pahani et al. (20)   | Yes            | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | Yes                       | NR                | Yes               |
| Pahani et al. (21)   | Yes            | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | Yes                       | Yes               | NR                |
| Ghazimoradi et al. (22)| Yes           | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | Yes                       | Yes               | Yes               |
| Mohammadi et al. (23)| Yes           | Yes                       | No                  | No           | Yes           | No                                          | Yes      | Yes                       | Yes               | Yes               |
| Mohammadi et al. (24)| Yes           | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | Yes                       | Yes               | No                |
| Safarian et al. (25) | Yes            | Yes                       | Yes                 | Yes          | Yes           | Yes                                         | Yes      | Yes                       | Yes               | Yes               |
| Shir Mohammadi et al. (26)| Yes        | Yes                       | Yes                 | No           | Yes           | Yes                                         | No       | Yes                       | No                | Yes               |

NR, not reported; RCTs, randomized clinical trials.

to M1 (associated with the release of pro-inflammatory mediators), resulting in a low-grade inflammatory state. Adipose tissue, especially visceral tissue, releases pro-inflammatory mediators such as interleukin 6 (IL-6), TNF-α, resistin, and reduces production of beneficial mediators such as adiponectin and IL-10. Obesity is related to hypertension, insulin resistance, and dyslipidemia, which are risk factors for establishing MS (31,39-41).

Curcumin has been shown to decrease glycemia and insulin levels and improve insulin resistance. It is also associated with reducing the levels of resistin, IL-1β, IL-6, IL-8, and TNF-α in patients with type 2 diabetes mellitus (T2DM). In these patients, it is shown that curcumin increases adiponectin levels (42). For these reasons, these compounds can interfere with glucose homeostasis, chronic diabetic complications, and vascular risk (43). Also, in patients with T2DM, this compound improved the lipid profile and the total antioxidant capacity (44,45), supporting evidence that this compound can reduce cardiometabolic risks (39,46-49).

In an animal model, the authors investigated the effects of different commercial supplements with Curcuma longa. The antioxidant activity and glucose diffusion and starch digestion were measured, and the results showed that the five different supplements were able to reduce glucose diffusion and the activity of α-glucosidase enzyme, and inhibited lipid peroxidation. However, the biological activity of the Curcuma longa supplements varies among them (50).

A study showed that the use of Curcuma longa extract in overweight or hypertension middle-aged and elderly participants significantly reduced glycemia, glycated hemoglobin, triglycerides, and increased HDL-C. The treated patients also showed significant improvement of chronic low-grade inflammation, contributing to the amelioration of metabolic disorders (51). Figure 3 shows the effects of curcumin in the components of the MS.

A recent systematic review and meta-analysis to investigate the effects of curcuminoids on triglycerides, cholesterol, LDL, and HDL of adults with prediabetes, diabetes, overweight, dyslipidemia, MS, or nonalcoholic fatty liver disease performed by Yuan et al. (52) showed that curcuminoids can significantly improve lipid profile in these subjects. Moreover, Ganjali et al. (53) showed that curcumin
can modulate biomarkers of HDL-C function, such as the activity and the levels of apolipoprotein-AI, cholesteryl ester transfer protein, lecithin cholesterol acyl transferase, paraoxonase 1, and Myeloperoxidase. Besides that, this compound can subsequently ameliorate conditions in which HDL-C is dysfunctional and could work as a promising therapeutic drug in the future.

Choi et al. (54) evaluated the association among *Curcuma longa* consumers with hypertension and blood levels of heavy metals in Korean subjects. They found that participants that had intake a curry dish more than once per month during the previous year exhibited significantly reduced Pb, Hg, and Cd concentrations. The concentrations of these metals were significantly linked to the prevalence of hypertension. Indeed, the *Curcuma longa* intake decreased the risk of hypertension prevalence. In mice, when captopril was associated with *Curcuma longa*, there was a reduction of cardiac muscle and left ventricle thickness in animals with hypertension, suggesting that this association can prevent cardiac complications of hypertension (55).

*Curcuma longa* can reduce body weight and body fat percentage in obese and overweight females. Furthermore, it can prevent excessive weight gain and play an important role in regulating inflammatory reactions observed in the overweight subjects, helping reduce the body-weight excess (56,57).

In addition to these studies described above, it is possible to observe that the RCTs presented in Table 1 also show positive effects of curcumin in MS patients; however, the parameters evaluated were varied. Only two studies investigated the effects of curcumin on dyslipidemia (16,17), and both found an improvement in the lipid profile. One study showed the benefits of reducing body weight, waist circumference, and fat percentage (19). The other studies did not assess the outcomes in parameters directly related to the diagnosis of MS. One study showed improvement in superoxide dismutase activity and improved malonaldehyde levels and reduced C reactive protein (CRP) levels (18). The levels of adiponectin were increased, and leptin levels were decreased in other RCTs (20). The pro-inflammatory parameters (TNF-α and IL-6) were also improved in one RCT (21). Safarian et al. (25) showed improvement in the levels of Zn/Cu in patients treated with curcumin. The remaining four included RCT found no effects of curcumin on vitamin E levels (23), oxidant-antioxidant balance (22), anti-Hsp 27 (24), and cathepsin D levels (26). The improvement in body weight, glycemia, lipids, and biomarkers of inflammation reduce the risk of developing diabetes, CVD, cancer, and other conditions associated with the presence of MS (Figures 4,5).

However, some relevant biases can be mentioned in...
these studies, such as the high number of patients who discontinued the study, not reporting adverse events, and not-blinded studies. Furthermore, as described above, many of the eleven studies included in this review used the same patients and evaluated different variables.

Despite the limitations presented by the included studies, the results of this review may help professionals when using Curcuma longa in the management of patients with MS.

**Conclusions**

We conclude that the use of Curcuma longa can help control risk factors in patients with MS. However, more clinical trials are necessary to show the doses and formulations that should be used in the prevention or as adjuvants in the treatment of metabolic conditions associated with MS.

**Limitations**

The limitations of this study lie in the fact that the included studies are very heterogeneous with regard to the doses administered and the formulation of Curcuma longa.

**Summary**

Curcuma longa and curcumin show impressive anti-inflammatory and antioxidant actions and can improve the risk factors that characterize the presence of MS.
Figure 5 The role of curcumin against inflammation and oxidative stress observed in MS. ↑, increase; ↓, decrease; Φ, inhibition. ROS, reactive oxygen species; RNS, reactive nitrogen species; MS, metabolic syndrome; SOD, superoxide dismutase; GSH, reduced glutathione; NF-KB, nuclear factor kappa B; TNF-α, tumor necrosis factor-α; TGF-β, transforming growth factor beta; IL-6, interleukin 6; MCP-1, chemoattractant protein 1.

Acknowledgments

The authors declare attribution to Smart Servier (https://smart.servier.com/) due to the provision of some scientific images that were used in this article under an attribution license of public copyrights (https://creativecommons.org/licenses/by/3.0/) and under disclaimer of warranties. All Smart Servier’s images were not changed, except the heart image in the Figure 4, which had its color changed.
Funding: None.

Footnote

Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at https://dx.doi.org/10.21037/lcm-21-25

Conflict of Interests: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/lcm-21-25). SMB serves as an unpaid editorial board member of Longhua Chinese Medicine from Jun 2020 to May 2022. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Peer Review File: Available at https://dx.doi.org/10.21037/lcm-21-25

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Wong SK. Repurposing New Use for Old Drug Chloroquine against Metabolic Syndrome: A Review on Animal and Human Evidence. Int J Med Sci 2021;18:2673-88.
2. Tofano RJ, Pescinni-Salzedas LM, Chagas EFB, et al. Association of Metabolic Syndrome and Hyperferritinemia in Patients at Cardiovascular Risk. Diabetes Metab Syndr Obes 2020;13:3239-48.
3. Yarmohammadi F, Ghasemzadeh Rahbardar M, Hosseinzadeh H. Effect of eggplant (Solanum melongena) on the metabolic syndrome: A review. Iran J Basic Med Sci 2021;24:420-7.
4. Eisvand F, Razavi BM, Hosseinzadeh H. The effects of Ginkgo biloba on metabolic syndrome: A review. Phytother Res 2020;34:1798-811.
5. Lee K, Kim J. Serum vitamin D status and metabolic syndrome: a systematic review and dose-response meta-analysis. Nutr Res Pract 2021;15:329-45.
6. Schaffer M, Schaffer PM, Bar-Sela G. An update on Curcuma as a functional food in the control of cancer and inflammation. Curr Opin Clin Nutr Metab Care 2015;18:605-11.
7. Mazieiro R, Frizon RR, Barbalho SM, et al. Is Curcumin a Possibility to Treat Inflammatory Bowel Diseases? J Med Food 2018;21:1077-85.
8. Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2017;57:2889-95.
9. Cunha Neto F, Marton LT, de Marqui SV, et al. Curcuminoids from Curcuma Longa: New adjuvants for the treatment of crohn’s disease and ulcerative colitis? Crit Rev Food Sci Nutr 2019;59:2136-43.
10. Goulart RA, Barbalho SM, Lima VM, et al. Effects of the Use of Curcumin on Ulcerative Colitis and Crohn’s Disease: A Systematic Review. J Med Food 2021;24:675-85.
11. Amalraj A, Pius A, Gopi S, et al. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review. J Tradit Complement Med 2017;7:205-33.
12. Barbalho SM, de Sousa Gonzaga HF, de Souza GA, et al. Dermatological effects of Curcuma species: a systematic review. Clin Exp Dermatol 2021;46:825-33.
13. Goulart RA, Barbalho SM, Rubira CJ, et al. Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2020;14:1171-9.
14. Bandyopadhyay D. Farmer to pharmacist: curcumin as an anti-invasive and antimetastatic agent for the treatment of cancer. Front Chem 2014;2:113.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-W64.
16. Yang YS, Su YF, Yang HW, et al. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res 2014;28:1770-7.
17. Panahi Y, Khalili N, Hosseini MS, et al. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med
18. Panahi Y, Hosseini MS, Khalili N, et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutr 2015;34:1101-8.

19. Di Pierro F, Bressan A, Ranaldi D, et al. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. Eur Rev Med Pharmacol Sci 2015;19:4195-202.

20. Panahi Y, Hosseini MS, Khalili N, et al. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition 2016;32:1116-22.

21. Panahi Y, Hosseini MS, Khalili N, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother 2016;82:578-82.

22. Ghazimoradi M, Saberi-Karimian M, Mohammadi F, et al. The Effects of Curcumin and Curcumin-Phospholipid Complex on the Serum Pro-oxidant-Antioxidant Balance in Subjects with Metabolic Syndrome. Phytother Res 2017;31:1715-21.

23. Mohammadi A, Sadeghnia HR, Saberi-Karimian M, et al. Effects of Curcumin on Serum Vitamin E Concentrations in Individuals with Metabolic Syndrome. Phytother Res 2017;31:657-62.

24. Mohammadi F, Ghazi-Moradi M, Ghayour-Mobarhan M, et al. The Effects of Curcumin on Serum Heat Shock Protein 27 Antibody Titers in Patients with Metabolic Syndrome. J Diet Suppl 2019;16:592-601.

25. Safarian H, Parizadeh SMR, Saberi-Karimain M, et al. The Effect of Curcumin on Serum Copper and Zinc and Zn/Cu Ratio in Individuals with Metabolic Syndrome: A Double-Blind Clinical Trial. J Diet Suppl 2019;16:625-34.

26. Shir)mohammadi L, Ghayour-Mobarhan M, Saberi-Karimian M, et al. Effect of Curcumin on Serum Cathepsin D in Patients with Metabolic Syndrome. Cardiovasc Hematol Disord Drug Targets 2020;20:116-21.

27. Tófano RJ, Barbalho SM, Bechara MD, et al. Hypertension, C Reactive Protein and Metabolic Profile: What is the Scenario in Patients Undergoing Arteriography? J Clin Diagn Res 2017;11:BC19-23.

28. Su Z, Zeng K, Feng B, et al. Kun-Dan Decoction Ameliorates Insulin Resistance by Activating AMPK/mTOR-Mediated Autophagy in High-Fat Diet-Fed Rats. Front Pharmacol 2021;12:670151.

29. Ishaku SM, Karima T, Oboirien KA, et al. Metabolic syndrome following hypertensive disorders in pregnancy in a low-resource setting: A cohort study. Pregnancy Hypertens 2021;25:129-35.

30. de Oliveira Dos Santos AR, de Oliveira Zanuso B, Miola VFB, et al. Adipokines, Myokines, and Hepatokines: Cross-talk and Metabolic Repercussions. Int J Mol Sci 2021;22:2639.

31. Barbalho SM, Bechara MD, Quesada K, et al. Síndrome metabólica, aterosclerose e inflamação: triâde indissociável? J Vasc Bras 2015;14:319-27.

32. Ning J, Zhang Y, Hu H, et al. Association between ambient particulate matter exposure and metabolic syndrome risk: A systematic review and meta-analysis. Sci Total Environ 2021;782:146855.

33. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.

34. Juanola O, Martínez-López S, Francés R, et al. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227.

35. Kim HB, Kim GJ, Han KD, et al. Changes in metabolic syndrome status and risk of laryngeal cancer: A nationwide cohort study. PLoS One 2021;16:e0252872.

36. Keskin H, Cadirci K, Gungor K, et al. Association between TSH Values and GFR Levels in Euthyroid Cases with Metabolic Syndrome. Int J Endocrinol 2021:2021:8891972.

37. Schönfeld P, Reiser G. How the brain fights fatty acids’ toxicity. Neurochem Int 2021;148:105050.

38. Hosseini A, Razavi BM, Banach M, et al. Quercetin and metabolic syndrome: A review. Phytother Res 2021. [Epub ahead of print]. doi: 10.1002/ptr.7144.

39. Marton L T, Pescinini-E-Salzedas LM, Camargo MEC, et al. The Effects of Curcumin on Diabetes Mellitus: A Systematic Review. Front Endocrinol (Lausanne) 2021;12:669448.

40. Saffarionpour S, Diosady LL. Curcumin, a potent therapeutic nutraceutical and its enhanced delivery and bioaccessibility by pickering emulsions. Drug Deliv Transl
41. Zhang P, Sun X, Jin H, et al. Association Between Obesity Type and Common Vascular and Metabolic Diseases: A Cross-Sectional Study. Front Endocrinol (Lausanne) 2019;10:900.

42. Hajavi J, Momtazi AA, Johnston TP, et al. Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes. J Cell Biochem 2017;118:4170-82.

43. Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin 2018;39:1176-88.

44. Panahi Y, Khalili N, Sahebi E, et al. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology 2017;25:25-31.

45. Panahi Y, Khalili N, Sahebi E, et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complement Ther Med 2017;33:1-5.

46. Cicero AFG, Colletti A, Bajraktari G, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev 2017;75:731-67.

47. Johnston TP, Korolenko TA, Pirro M, et al. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res 2017;120:219-25.

48. Ward N, Sahebkar A, Banach M, et al. Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. Curr Opin Lipidol 2017;28:495-501.

49. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 2014;11:123.

50. Guerrero-Romero F, Simental-Mendía LE, Martínez-Aguilar G, et al. Hypoglycemic and antioxidant effects of five commercial turmeric (Curcuma longa) supplements. J Food Biochem 2020;44:e13389.

51. Uchio R, Muroyama K, Okuda-Hanafusa C, et al. Hot Water Extract of Curcuma longa L. Improves Serum Inflammatory Markers and General Health in Subjects with Overweight or Prehypertension/Mild Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2019;11:1822.

52. Yuan F, Dong H, Gong J, et al. A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effects of Turmeric and Curcuminoids on Blood Lipids in Adults with Metabolic Diseases. Adv Nutr 2019;10:791-802.

53. Ganjali S, Blesso CN, Banach M, et al. Effects of curcumin on HDL functionality. Pharmacol Res 2017;119:208-18.

54. Choi JW, Oh C, Shim SY, et al. Reduction in Prevalence of Hypertension and Blood Heavy Metals among Curry-Consumed Korean. Tohoku J Exp Med 2018;244:219-29.

55. Hijriani N, Yusetyani L, Hasmono D. The effect of curcuma (Curcuma xanthorrhiza roxb.) extract as an adjuvant of captopril therapy on cardiac histopathology of male mice (Mus musculus) with hypertension. J Basic Clin Physiol Pharmacol 2020. doi: 10.1515/jbcpp-2019-0280.

56. Latif R, Mumtaz S, Al Sheikh MH, et al. Effects of Turmeric on Cardiovascular Risk Factors, Mental Health, and Serum Homocysteine in Overweight, Obese Females. Altern Ther Health Med 2021;27:114-9.

57. Jarząb A, Kukula-Koch W. Recent Advances in Obesity: The Role of Turmeric Tuber and Its Metabolites in the Prophylaxis and Therapeutical Strategies. Curr Med Chem 2018;25:4837-53.